hotspot -WSS

hotspot

author：focus 2025-08-28 08:40:36 - browse：97893

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Setback for rare diseases as Taysha Gene Therapies pulls back

entertainment

hotspot

Wikipedia

WSS

New lawsuit accuses health insurer Cigna of denying claims in bulk

WHO recommends second malaria vaccine

Device maker Teleflex to acquire urology company for $600M

How doctors’ personal politics affect patients

The United States is paying nearly triple for new Covid vaccines

WHO recommends second malaria vaccine

knowledge

hotspot

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

New Alzheimer's drugs heat up race for early detection blood tests

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Search called off for baby washed away in Pennsylvania flash flood

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What we owe ALS patients — and why one company fell short

United colonoscopy coverage change 'may cost lives,' doctors say

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

In age of alternative facts, a scholarly course on calling out crap

WHO recommends second malaria vaccine

entertainment

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Why patients can’t get everything they want on drug pricing

In the gardens at Boston Children's Hospital, families find sanctuary

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

The Karikó problem: Lessons for funding basic research

The United States is paying nearly triple for new Covid vaccines

entertainment

hotspot

Wikipedia

focus